Figure 1
Receiver-operating characteristic curves for fIGF-1 as a predictive maker for PFS benefit at 3–6 months in PCF-treated patients (10–20 mg kg−1 F).
Figure 1 | British Journal of Cancer
Receiver-operating characteristic curves for fIGF-1 as a predictive maker for PFS benefit at 3–6 months in PCF-treated patients (10–20 mg kg−1 F).
